Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists who Treat CLL (US)

Analysis of: China Muscles In On The Generics Industry (www.pharmalot.com)
China, buoyed by its recent economic boom, is invading industrilaized nation markets with many generic compounds , from pain killers to AIDS drugs. Chinese drugs are cheap, but have reputation for poor quality , especially with recent heparin fiasco. India has had a good track record with generics and...
Analysis of: Drug Brings ImClone in From Cold (online.wsj.com)
Well we know that the lung cancer trial  http://online.wsj.com/article/SB121227163771635641.html?mod=2_1566_topbox was a bust so far. What other "good news" do we await
Analysis of: Erbitux Slightly Boosts Survival in Cancer Study (online.wsj.com)
Basically?? It's a bust until we see subset analysis. It is possible adenocarcinomas as well as non smokers will show better survival
Analysis of: Hints of Progress in Drugs Treating Brain Cancer (www.nytimes.com)
For the first time in decades, several drugs like Temodar and Avastin and tumor vaccines ( Avant and others) have shown increased overall survival even in adavnaced and recurrent brain tumors as glioblastoma multiforme. Several agents are in the pipeline, and more Big Pharma involvement is expected...
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). (www.abstract.asco.org)
The epidermal growth factor antagonist Erbitux did not improve response rates in newly diagnosed patients with advanced non-small cell lung cancer ( NSCLC).  Many patients had hypersensitivity reactions to Cetuximab, which has to be content with its role in colon cancer treatment and to some extent...
Analysis of: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia (bloodjournal.hematologylibrary.org)
In a clinical trial from MD Anderson, Celgene's oral immunomodulatory agent , Revlimid showed a modest, yet impressive, overall response rate of 32% in patients with refractory, heavily pre-treated CLL. With already proven efficacy in other hematological malignancies, like multiple myeloma, myelofibrosis,...
Analysis of: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia (bloodjournal.hematologylibrary.org)
Revlimid has activity in Chronic Lymphatic Leukemia (CLL) in addition to myeloma and myelodysplasia.
Analysis of: Mixed Outcomes in Laparoscopy for Prostates (www.nytimes.com)
Higher recurrance rate???!!!
Analysis of: Hints of Progress in Drugs Treating Brain Cancer (www.nytimes.com)
     While no slam dunk cures are noted, drugs such as Avastin (Genentech), Temodar (Schering-Plough) &  Avant/Pfizer  vaccines  are making an impact on  "Brain Cancer"  survival.
Analysis of: Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors (www.pipelinereview.com)
Proteolix's selective proteosome inhibitor PR-171 have shown pre-clinical activity in slid tumor animal models, but only a small Phase Ib clinical trial of 14 patients have been completed. based on spectrum of activity of a similar compound ( Valcade, Mellinium), the main efficacy of this agent...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next101 to 110 of 701

Analytics


Generated at 2009-01-07T13:00:17.563